

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (currently amended) A composition comprising a complementary pair of siRNA oligomeric compounds consisting of:
 - a first oligomeric compound and a second oligomeric compound, wherein:
~~said the~~ first oligomeric compound and ~~said the~~ second oligomeric compound are not covalently linked to each other;
 - at least a portion of ~~said the~~ first oligomeric compound is complementary to at least a portion of ~~said the~~ second oligomeric compound and to a target nucleic acid; and
~~at least one of said the first and said second oligomeric compounds compound comprises at least one conjugate moiety, wherein said at least one conjugate moiety is a steroid attached to a the 3'-terminal monomeric subunit of said at least one the oligomeric compound and wherein said at least one conjugate moiety is a steroid the second oligomeric compound comprises a steroid attached to the 5'-terminal monomeric subunit of the oligomeric compound.~~
- 2-3. (canceled)
4. (currently amended) The composition of claim 1 wherein each of ~~said the~~ first and second oligomeric compounds comprises 10 to 40 nucleotides.
5. (currently amended) The composition of claim 1 wherein each of ~~said the~~ first and second oligomeric compounds comprises 18 to 30 nucleotides.
6. (currently amended) The composition of claim 1 wherein each of ~~said the~~ first and second oligomeric compounds comprises 21 to 24 nucleotides.
- 7-8. (canceled)

9. (currently amended) The composition of claim 1 wherein said the second oligomeric compound comprises an oligonucleotide having a plurality of ribose nucleotide units.

10-20. (canceled)

21. (currently amended) The composition of claim 1 wherein said at least one conjugate moiety the steroid attached to at least one of the first and second oligomeric compounds is attached ~~to said first or second oligomeric compounds~~ through a linker.

22-23. (canceled)

24. (currently amended) The composition of claim 1 wherein said at least one conjugate moiety the steroid attached to at least one of the first and second oligomeric compounds is cholesterol or a cholesterol derivative.

25. (currently amended) The composition of claim 1 wherein said at least one conjugate moiety the steroid attached to at least one of the first and second oligomeric compounds binds to low-density lipoprotein.

26-35. (canceled)

36. (currently amended) The composition of claim 1 wherein said at least one conjugate moiety the steroid attached to at least one of the first and second oligomeric compounds enhances the pharmacokinetic or pharmacodynamic properties of said the composition oligomeric compound.

DOCKET NO.: CHEM0005US.P1/ISIS-5782

PATENT

Application No.: 10/700,971

Office Action Dated: November 25, 2009

37. (currently amended) The composition of claim 1 wherein said the composition has first and second oligomeric compounds have improved cellular uptake properties as compared with to the same composition oligomeric compounds having no conjugate moiety steroids attached.

38-100. (canceled)

101. (original) A pharmaceutical composition comprising the composition of claim 1 and a pharmaceutically acceptable carrier.

102-109. (canceled)